Market Cap 2.88B
Revenue (ttm) 182.95M
Net Income (ttm) -115.55M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -63.16%
Debt to Equity Ratio 0.22
Volume 727,000
Avg Vol 668,906
Day's Range N/A - N/A
Shares Out 42.21M
Stochastic %K 7%
Beta 0.81
Analysts Strong Sell
Price Target $79.43

Company Profile

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is also developing TP-04 for the treatment of Ocular Rosacea; TP-05 for potential Lyme disease prophylaxis; and community...

Industry: Biotechnology
Sector: Healthcare
Phone: 949 409 1801
Address:
15440 Laguna Canyon Road, Suite 160, Irvine, United States
stocksUP59
stocksUP59 Oct. 24 at 5:32 PM
XDEMVY is a hell of a product. I've heard only good things from multiple ODs. Easy blockbuster... $TARS will be acquired in 2026, no question about it
0 · Reply
BostonNorth
BostonNorth Oct. 23 at 2:56 PM
$TARS blessing in disguise TARS BULLS. For anyone that believes in the next EpiPen first and only needle free alternative Neffy (just launched worldwide ) and hives treatment (currently in under the radar phase two trials)! If November earnings is a beat coupled with additional xUS approvals (Canada, New Zealand & Australia) all but Australia expected before year end…combined with lower ATS off exchange trading. Consider this an ROCKET ship ready to take off to another atmosphere. Lol. Good luck to all and not financial advice.
1 · Reply
Creyedr
Creyedr Oct. 23 at 1:04 AM
$MSPR @GODX Look into $VVOS, $GRRR, $TARS ... all great buys with huge upside and minimal risk at current levels.
0 · Reply
JFais
JFais Oct. 22 at 1:33 PM
$TARS what I love about community (critical feedback). Some folks not happy I took profits & moved on
1 · Reply
JFais
JFais Oct. 21 at 10:26 PM
$TARS (NP) Trade Summary
1 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Oct. 21 at 7:40 PM
$FOLD continues to trade at lower multiples of projected sales versus 3 peers with like dollar forecasts & gross margin profiles. FOLD is currently defending its patent rights against a generic pharma hoping to sell a biosimilar. We suspect this could be the reason why FOLD does not trade at like multiples versus its peers $MIRM $TARS $KNSA Again by peers we mean those commercial-stage bios with similar revenue projections & patent lives. This is not investment advice. $IBB
2 · Reply
JFais
JFais Oct. 20 at 9:24 PM
Congrats FinnTrades/ @FeldtInvesting 👏👏 $NKTR $TARS $TGTX Glad you are taking a step back to enjoy the wins- can always reenter (new setups) when ready on your own terms 👍
1 · Reply
TanWispers
TanWispers Oct. 20 at 12:28 PM
$TARS consolidating at upper range. Entry 41.60, stop 40.20, PT 45.00. Break and hold above 42.20 unlocks the move. Volume over 1.6 times 20D is the tell. 🎯
0 · Reply
SouthHaus
SouthHaus Oct. 20 at 11:19 AM
$TARS H C Wainwright raises target price to $88.
0 · Reply
Quantumup
Quantumup Oct. 20 at 10:51 AM
H.C. Wainwright⬆️the PT on $TARS to $88 from $72, reit'd at Buy, and said, Heading into earnings and based on our positive sentiment towards the ongoing XDEMVY launch, we have re-evaluated our slope of the launch, adjusting our market penetrations to align with the demonstrated trajectory of drug sales. We note over the most recent quarters, reported XDEMVY sales have ranged from approximately 18% to 31% QoQ growth for 2025, which we believe can be supported over the near term based on current commercial initiatives discussed below. More specifically, we have: (1) increased our penetration and revenue estimates in the coming years driven by expansion of the prescriber base with over 20K ECPs writing for XDEMVY; and (2) increased our peak estimated 2036 market penetration up from 20% to 25%. We have raised our sales estimates within our model, and our conviction is based on the XDEMVY launch trajectory. We reiterate our Buy rating and increase our price target to $88 per share from $72.
0 · Reply
Latest News on TARS
Tarsus to Participate in Upcoming Investor Conferences

Aug 27, 2025, 5:00 PM EDT - 2 months ago

Tarsus to Participate in Upcoming Investor Conferences


Top 2 Health Care Stocks That May Fall Off A Cliff In August

Aug 20, 2025, 8:46 AM EDT - 2 months ago

Top 2 Health Care Stocks That May Fall Off A Cliff In August

PINC


Tarsus Pharmaceuticals: The "Get Big Fast" Approach Could Pay Off

May 12, 2025, 12:28 PM EDT - 5 months ago

Tarsus Pharmaceuticals: The "Get Big Fast" Approach Could Pay Off


Tarsus Announces Proposed $100.0 Million Public Offering

Mar 12, 2025, 4:12 PM EDT - 8 months ago

Tarsus Announces Proposed $100.0 Million Public Offering


Tarsus Pharma: Strong Execution In Xdemvy Commercialization

Mar 11, 2025, 12:36 PM EDT - 8 months ago

Tarsus Pharma: Strong Execution In Xdemvy Commercialization


Tarsus to Participate in Upcoming Investor Conference

Mar 6, 2025, 5:00 PM EST - 8 months ago

Tarsus to Participate in Upcoming Investor Conference


Tarsus to Participate at Upcoming Investor Conferences

Mar 5, 2024, 4:30 PM EST - 1 year ago

Tarsus to Participate at Upcoming Investor Conferences


Tarsus Announces Pricing of $100.0 Million Public Offering

Mar 1, 2024, 12:07 AM EST - 1 year ago

Tarsus Announces Pricing of $100.0 Million Public Offering


stocksUP59
stocksUP59 Oct. 24 at 5:32 PM
XDEMVY is a hell of a product. I've heard only good things from multiple ODs. Easy blockbuster... $TARS will be acquired in 2026, no question about it
0 · Reply
BostonNorth
BostonNorth Oct. 23 at 2:56 PM
$TARS blessing in disguise TARS BULLS. For anyone that believes in the next EpiPen first and only needle free alternative Neffy (just launched worldwide ) and hives treatment (currently in under the radar phase two trials)! If November earnings is a beat coupled with additional xUS approvals (Canada, New Zealand & Australia) all but Australia expected before year end…combined with lower ATS off exchange trading. Consider this an ROCKET ship ready to take off to another atmosphere. Lol. Good luck to all and not financial advice.
1 · Reply
Creyedr
Creyedr Oct. 23 at 1:04 AM
$MSPR @GODX Look into $VVOS, $GRRR, $TARS ... all great buys with huge upside and minimal risk at current levels.
0 · Reply
JFais
JFais Oct. 22 at 1:33 PM
$TARS what I love about community (critical feedback). Some folks not happy I took profits & moved on
1 · Reply
JFais
JFais Oct. 21 at 10:26 PM
$TARS (NP) Trade Summary
1 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Oct. 21 at 7:40 PM
$FOLD continues to trade at lower multiples of projected sales versus 3 peers with like dollar forecasts & gross margin profiles. FOLD is currently defending its patent rights against a generic pharma hoping to sell a biosimilar. We suspect this could be the reason why FOLD does not trade at like multiples versus its peers $MIRM $TARS $KNSA Again by peers we mean those commercial-stage bios with similar revenue projections & patent lives. This is not investment advice. $IBB
2 · Reply
JFais
JFais Oct. 20 at 9:24 PM
Congrats FinnTrades/ @FeldtInvesting 👏👏 $NKTR $TARS $TGTX Glad you are taking a step back to enjoy the wins- can always reenter (new setups) when ready on your own terms 👍
1 · Reply
TanWispers
TanWispers Oct. 20 at 12:28 PM
$TARS consolidating at upper range. Entry 41.60, stop 40.20, PT 45.00. Break and hold above 42.20 unlocks the move. Volume over 1.6 times 20D is the tell. 🎯
0 · Reply
SouthHaus
SouthHaus Oct. 20 at 11:19 AM
$TARS H C Wainwright raises target price to $88.
0 · Reply
Quantumup
Quantumup Oct. 20 at 10:51 AM
H.C. Wainwright⬆️the PT on $TARS to $88 from $72, reit'd at Buy, and said, Heading into earnings and based on our positive sentiment towards the ongoing XDEMVY launch, we have re-evaluated our slope of the launch, adjusting our market penetrations to align with the demonstrated trajectory of drug sales. We note over the most recent quarters, reported XDEMVY sales have ranged from approximately 18% to 31% QoQ growth for 2025, which we believe can be supported over the near term based on current commercial initiatives discussed below. More specifically, we have: (1) increased our penetration and revenue estimates in the coming years driven by expansion of the prescriber base with over 20K ECPs writing for XDEMVY; and (2) increased our peak estimated 2036 market penetration up from 20% to 25%. We have raised our sales estimates within our model, and our conviction is based on the XDEMVY launch trajectory. We reiterate our Buy rating and increase our price target to $88 per share from $72.
0 · Reply
JarvisFlow
JarvisFlow Oct. 20 at 10:40 AM
HC Wainwright & Co. updates rating for Tarsus Pharmaceuticals ( $TARS ) to Buy, target set at 72 → 88.
0 · Reply
Biotechace
Biotechace Oct. 19 at 6:13 PM
$TARS Gurufocus GF Value $185.48
0 · Reply
YungBullHOLLA
YungBullHOLLA Oct. 16 at 3:57 PM
$TARS this company is pure sexy
0 · Reply
Hawksssss
Hawksssss Oct. 16 at 1:59 PM
$TARS wow another all time high
0 · Reply
Biotechace
Biotechace Oct. 16 at 11:46 AM
0 · Reply
Biotechace
Biotechace Oct. 16 at 11:37 AM
$TARS someone on here kept mentioning the 80 RSI and this would retrace downward when it hit around 70. They said if it didn't it might mean there was a buyout. It didn't (or hasn't) retraced downward. It blew right through the 80RSI.
0 · Reply
TheMonz
TheMonz Oct. 15 at 7:59 PM
0 · Reply
RonIsWrong
RonIsWrong Oct. 15 at 7:50 PM
$TARS beauty
0 · Reply
Biotechace
Biotechace Oct. 15 at 3:30 PM
$TARS maybe all of those high dollar cars I saw at HQ's the other day were Abbvie reps?
1 · Reply
RonIsWrong
RonIsWrong Oct. 15 at 3:16 PM
$TARS through the consolidation
1 · Reply
Hawksssss
Hawksssss Oct. 15 at 2:19 PM
$TARS another all time high
0 · Reply
TheMonz
TheMonz Oct. 15 at 2:13 PM
0 · Reply